Please login to the form below

Not currently logged in

Pulmicort Respules

This page shows the latest Pulmicort Respules news and features for those working in and with pharma, biotech and healthcare.

AZ gets injunction to protect Pulmicort Respules

AZ gets injunction to protect Pulmicort Respules

Actavis has been blocked from selling its generic version of AstraZeneca's asthma drug Pulmicort Respules five just days after the product was launched. ... For the 12 months ended June 30 2014, total sales of Pulmicort Respules and an authorised generic

Latest news

  • AZ loses Pulmicort Respules protection in US AZ loses Pulmicort Respules protection in US

    Court also denied AZ’s request for a permanent injunction.  . AstraZeneca (AZ) was dealt a major blow by a US court after a key patent protecting its Pulmicort Respules product was ... AZ has been fighting to protect its Pulmicort Respules franchise

  • AstraZeneca hit by US Pulmicort patent ruling AstraZeneca hit by US Pulmicort patent ruling

    If upheld, the decision will cut more than five years from the exclusivity period for Pulmicort Respules (budesonide), which is due to expire in the US in 2018 with a paediatric ... Sales of AZ's Pulmicort range were $866m last year worldwide and $233m

  • AZ discontinues asthma medicine

    AstraZeneca is to discontinue production of an inhaled version of its asthma medication Pulmicort due to 'manufacturing issues'. ... Other unaffected products include AZ's Pulmicort Turbuhaler, Pulmicort Respules and Pulmicort Flexhaler.

  • Generics and legal costs affect AZ profits

    The core products affected by generic competition are Toprol-XL (metoprolol succinate) – a high blood pressure medication, asthma treatment Pulmicort Respules (budesonide inhalation suspension) and the company's breast cancer drug

  • Positive Q1 figures for AstraZeneca

    Sales of asthma drug, Symbicort increased in all markets globally, while sales of Pulmicort were down 37 per cent in the US. ... The impact on sales of Pulmicort Respules that can be attributed to Teva's generic budesonide inhalation suspension product

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Why precision medicine demands precision engagement
The speed of innovation brings its own challenges, says cloud computing expert...
Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...